Bezlotoxumab
Bezlotoxumab (pronunciation: bez-loh-TOX-yoo-mab) is a monoclonal antibody used as a medication to prevent the recurrence of Clostridium difficile infection (CDI) in patients who are at high risk of CDI recurrence.
Etymology
The name "Bezlotoxumab" is derived from its function. "Bezlo" is a prefix used in pharmacology for drugs that act against toxins, "toxu" refers to toxin, and "mab" is a suffix used for monoclonal antibodies.
Pharmacology
Bezlotoxumab works by binding to Clostridium difficile toxin B, preventing it from interacting with its target in the human body. This reduces the damage caused by the toxin and helps to prevent the recurrence of CDI.
Usage
Bezlotoxumab is administered as an intravenous infusion, usually in a hospital or clinic setting. It is typically used in conjunction with an antibiotic treatment for CDI.
Side Effects
Common side effects of bezlotoxumab include nausea, fever, and headache. Serious side effects may include allergic reactions, heart failure, and infection.
Related Terms
External links
- Medical encyclopedia article on Bezlotoxumab
- Wikipedia's article - Bezlotoxumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski